ArticleGut2023
Eradicating
Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03900910 (A Gastric Cancer Prevention Program for Aboriginal People Living in the Remote Areas), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Gastric Cancer Prevention Program for Aboriginal People Living in the Remote Areas
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- Trial
- Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial.JAMA · 2024Trial
- Helicobacter pylori in Israel: real-life data from a large database on frequency of non-invasive testing, follow-up testing and risk factors for infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- From screening to surveillance: integrated prevention ofThe Lancet regional health. Western Pacific · 2026Review
- Seroprevalence of Helicobacter pylori Infection Among Asymptomatic Patients Served by a Safety-Net Healthcare System.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- The effects of family-based Helicobacter pylori infection control and management strategies in Southwest China households: a two-year retrospective cohort study.BMC gastroenterology · 2025Article
- Helicobacter pylori Screening and Eradication in Junior High School Students in Yokosuka, Japan: Prevalence, Eradication Rates, and Challenges.Journal of gastroenterology and hepatology · 2025Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Helicobacter pylori Detection Based on Synergistic Electromagnetic and Chemical Enhancement of Surface-Enhanced Raman Scattering in 3D Hotspot-Activated Gold Nanorods/Nano Mica Platelets/ZnO Quantum Dots.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Translating evidence into action: overcoming barriers to gastric cancer prevention in Aotearoa.Journal of the Royal Society of New Zealand · 2025Review
- Parental Knowledge and Attitudes Towards Helicobacter Pylori Screening in Adolescents: A School-Based Questionnaire Study Among Guardians of Junior High School Students in Yokosuka City, Japan.Journal of gastrointestinal cancer · 2024Article
- Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control.Viruses · 2024Review
- Assessment ofHeliyon · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
27 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveScreening and eradication of
designWe enrolled residents aged 20-60 years from Taiwanese indigenous communities to receive a course of test, treat, retest and re-treat initial treatment failures with the
resultsBetween 24 September 2018 and 31 December 2021, 15 057 participants (8852 indigenous and 6205 non-indigenous) were enrolled, with a participation rate of 80.0% (15 057 of 18 821 invitees). The positivity rate was 44.1% (95% CI 43.3% to 44.9%). In the proof-of-concept study with 72 indigenous families (258 participants), family members of a positive index case had 1.98 times (95% CI 1.03 to 3.80) higher prevalence of
conclusionA high participation rate, a high eradication rate of TRIAL REGISTRATION NUMBER: NCT03900910.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.